HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide
0.1.0 - CI Build

HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

## ValueSet: ESMO-MCBS Evaluation Form

Official URL: https://standards.digital.health.nz/fhir/ValueSet/sact-esmo-mcbs-evaluation-form | Version: 0.1.0
Active as of 2026-05-21 | Computable Name: EsmoMcbsEvaluationForm

The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale

References

- ESMO-MCBS Score

### Logical Definition (CLD)

- Include all codes defined in `https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` version 📦0.1.0

### Expansion

Expansion performed internally based on codesystem ESMO-MCBS Evaluation Form v0.1.0 (CodeSystem)

This value set contains 12 concepts

System | Code | Display (en) | JSON | XML
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-1a | Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-1b | Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-2a | Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-2b | Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-2c | Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | ST-3 | Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-1a | Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-1b | Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-2a | Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-2b | Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-2c | Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies |  |
`https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form` | HM-3 | Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR |  |

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code